PSYCHPSYCHPSYCH
  • REPORT
  • THE PSYCH SUMMIT
  • NEWS & INSIGHTS
  • NEWSLETTER
  • COMPANIES
  • REPORT
  • THE PSYCH SUMMIT
  • NEWS & INSIGHTS
  • NEWSLETTER
  • COMPANIES
  • UNLOCKING THE COMMERCIAL POTENTIAL OF PSYCHEDELICS
    DOWNLOAD THE REPORT
    SUBSCRIBE TO NEWSLETTER

OUR MISSION

The global psychedelics industry is expected to be worth over US$100 billion with the potential to save $1 trillion on lost productivity, disrupting the way we approach healthcare. As attitudes towards psychedelics shift dramatically, we are witnessing an international rise in clinical trials, academic research and commercial investment. The use of psychedelics as medicine is set to open up a new industry at pace. We help investors, operators and regulators navigate the many opportunities through data, intelligence and networking.

PSYCH VIRTUAL INVESTOR SUMMIT
EUROPE AND ASIA

Join us on 21st April for the launch of our first PSYCH Investor Summit: Europe & Asia for a day of networking, pitches and keynotes.

The PSYCH Investor Summit: Europe & Asia is an opportunity to engage with distinguished industry leaders, rising entrepreneurs and global psychedelics investors to share insights and help develop this emerging frontier. 

OFFERING

We demystify the legislative and regulatory environment surrounding a variety of psychedelics, helping our clients to navigate the changing landscape of each region.

We provide market forecasts and estimates for potential savings to society/economy which are likely to result from psychedelic therapies over the next decade.

We identify and analyse emerging trends for individual psychedelic therapies and monitor innovation and developments in this exciting, burgeoning industry.

THE PSYCHEDELICS AS MEDICINE REPORT: SECOND EDITION

DISRUPTING MODERN HEALTHCARE

Medical psychedelics are experiencing a renaissance, pushing forward the frontiers of healthcare innovation. The Psychedelics as Medicine Report: Second Edition provides unparalleled consumer insights and market intelligence from experts and industry leaders, helping to guide investors, operators and regulators through this transient phase. Download your free copy now.


The Psychedelics as Medicine Report: Second Edition examines:

  • Proprietary consumer insights on attitudes, uses and behaviours
  • Deep dives into the most transformative compounds and companies
  • Key regulations, transformative trends and commercial opportunities

HIGHLIGHTS

PSYCH: What are the next steps
for investors?

PSYCH: What Lies Ahead?
The Future of Therapy

PSYCH: Psychedelics for
Substance Use

PSYCH: Lessons Learned from 50 Years of Psychedelic Activism

NEWS AND INSIGHTS

The Horizons ETFs Makes Q1 Update

The main exchange for listing psychedelics companies, Horizons Psychedelic Stock Index ETF, has completed its first quarterly rebalance of its holdings. Horizons ETFs has over US$17.5 billion of assets under management and 88 ETFs listed on major Canadian stock exchanges. Four psychedelics industry businesses have been added to the index, which includes: Algernon Pharmaceuticals, BetterLifeContinue reading

Read more

Australia to Provide $15m to Support Research into Psychedelic Medicines

Last week, the Australian government announced it would provide $15m of funding to support research into psychedelic medicines and their impact on treating mental health conditions. The Mental Illness Grant Opportunity represents a new approach towards the likes of psilocybin, MDMA and Ketamine for Australia, where it is hoped that further legislative action and researchContinue reading

Read more

First ketamine-assisted psychotherapy clinic opens in the UK

Laurie Higbed, Ben Sessa and Steve O’Brien: Awakn Life Sciences | Photograph: Joel Redman/The Guardian Awakn Life Sciences has opened a clinic offering ketamine-assisted psychotherapy in the UK, becoming the first of its kind in the country. The clinic’s lead, Dr Ben Sessa, said he wants to harness the “unique mental state” he claims theContinue reading

Read more

THE PSYCHEDELICS NEWSLETTER

Expert analysis and intelligence, straight to your inbox. Join industry insiders and subscribe for exclusive news, data and insights from across the psychedelics industry.

ISSUES

Issue 21

Issue 22

FOLLOW US ON TWITTER

PSYCH @psych_pp

Catch Richard Cheung, intellectual property and regulatory expert and General Counsel, @NoeticFund , at the first PSYCH Investor Summit: Europe & Asia on 21st April. For tickets to this day of thought-provoking insight and discussion, register here: https://www.eventbrite.co.uk/e/psych-investor-summit-europe-asia-tickets-141169055445

Twitter 1381200895266918400
PSYCH @psych_pp

Catch Peter Reitano (@digidharma), serial entrepreneur, consumer marketing expert & @gwellamushrooms Chief Executive Officer at the first PSYCH Investor Summit: Europe & Asia on 21st April. For tickets to this day of insight and discussion, register here: https://www.eventbrite.co.uk/e/psych-investor-summit-europe-asia-tickets-141169055445

Twitter 1380567933714366468
Rick Doblin, MAPS @RickDoblin

35 years ago today, I founded the Multidisciplinary Association for Psychedelic Studies (@MAPS).

Happy 35th anniversary, MAPS! https://twitter.com/MAPS/status/1380275203712815107

Twitter 1380276573648035844
PSYCH @psych_pp

Have you secured your free passes to the PSYCH Investor Summit? Join @BusinessInsider's @jesse_yeji, Palo Santo's @TimSchlidt, @fieldtriphealth's @RonanDLevy and @NoeticFund's Richard Cheung in conversation on psychedelic patents & IP on 21st April. https://www.eventbrite.co.uk/e/psych-investor-summit-europe-asia-tickets-141169055445

Twitter 1380244343576010752
PSYCH @psych_pp

🌏 Preparing for the PSYCH Investor Summit: Europe and Asia
💝 Exploring the potential to create ethical psychedelics companies

These and more, including updates from @entheonbiomed, @MindCureHealth, @TrypTherapeutic, @wesanahealth & @mindmedco.

https://psych.prohibitionpartners.com/psych_weekly/23/

Twitter 1379896097355796480
Awakn™ Life Sciences @awakn_ls

Catch our CEO, @AnthonyTennyson at the PSYCH Investor Summit on 21st April 2021 and gain invaluable insights into the nascent psychedelics industry.

The best part of it? It's free to attend.

Tickets available here: https://psych.prohibitionpartners.com/summit/

@psych_pp @BenSessa @LaurieOlivia2

Twitter 1379786418139103235
Load More...
+44 (0) 203 928 2814
31 New Inn Yard, Shoreditch, London EC2A 3EY

 

©2021 PP Intelligence LTD. (t/a PSYCH)

Privacy Policy